Ally Bridge Invests In Two European Biopharmaceutical Firms

Hong Kong-based cross-border healthcare investment firm Ally Bridge Group has completed investments in two European biopharmaceutical companies, Galenica AG of Switzerland and Nabriva of Austria and the U.S., further expanding the firm's global portfolio.

No Financial details were disclosed. The two investments follow Ally Bridge's previously deals privatizing China's WuXi PharmaTech and its investment in Tesaro, Inc., a U.S. oncology-focused biopharmaceutical company, and other global healthcare companies.

Galenica, through its subsidiary Vifor Pharma, provides iron supplements and therapeutics treating chronic kidney disease, a prevalent and steadily growing condition worldwide. The company, based in Bern, Switzerland, is expanding its franchise further into nephrology, and new areas such as cardiology, women's health and gastroenterology, from Europe to the U.S.